BC Extra | Oct 14, 2019
Company News

Oct. 14 Company Quick Takes: Shionogi, Ultragenyx, BridgeBio-Eidos and MolMed

Imbalance in deaths likely focus of Shionogi advisory panel meeting  Briefing documents for an Oct. 16 meeting of FDA’s Antimicrobial Drugs Advisory Committee to discuss IV cefiderocol from Shionogi & Co. Ltd. (Tokyo:4507) to treat...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Extra | Oct 11, 2017
Preclinical News

Researchers optimize gene editing for SCID

Researchers from Ospedale San Raffaele and elsewhere used zinc finger nuclease and CRISPR- Cas9 (CRISPR-associated protein 9)-based gene editing to correct hematopoietic stem/progenitor cells in animal models of SCID-X1, demonstrating improved gene editing protocols that...
BC Week In Review | Jul 11, 2016
Clinical News

Zalmoxis regulatory update

EMA’s CHMP recommended conditional approval of Zalmoxis from MolMed as an adjunctive treatment to aid immune reconstitution and reduce the risk of graft-versus-host disease (GvHD) in adults with high-risk hematological malignancies who are receiving a...
BC Extra | Jun 25, 2016
Company News

CHMP recommendations include Keytruda for NSCLC

EMA's CHMP recommended approval of PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for non-small cell lung cancer, as well as asthma treatment Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and cell...
BC Innovations | Feb 4, 2016
Tools & Techniques

Calibrating CARs

Instead of focusing on how to turn chimeric antigen receptor (CAR) T cells off when things go wrong, a group at the California Institute for Biomedical Research (Calibr) has engineered a universal CAR T cell...
BC Innovations | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
BC Week In Review | May 18, 2015
Company News

San Raffaele, MolMed deal

MolMed exercised an option to purchase a chimeric antigen receptor (CAR)- splice variant v6 of CD44 (CD44v6) from San Raffaele. MolMed said the compound has applications in hematological and solid tumors. The companies could not...
BC Week In Review | Apr 20, 2015
Financial News

MolMed completes rights offering

MolMed S.p.A. (Milan:MLM), Milan, Italy   Business: Cancer   Date completed: 2015-04-09   Type: Rights offering   Raised: EUR49.8 million ($52.6 million)   Shares: 187.3 million   Price: EUR0.27   Shares after offering: 421.5 million...
BC Week In Review | Oct 6, 2014
Financial News

MolMed completes private placement

MolMed S.p.A. (Milan:MLM), Milan, Italy   Business: Cancer   Date completed: 2014-09-26   Type: Private placement   Raised: EUR1.5 million ($1.9 million)   Shares: 3.1 million   Price: EUR0.49   Shares after offering: 234.1 million...
Items per page:
1 - 10 of 94
BC Extra | Oct 14, 2019
Company News

Oct. 14 Company Quick Takes: Shionogi, Ultragenyx, BridgeBio-Eidos and MolMed

Imbalance in deaths likely focus of Shionogi advisory panel meeting  Briefing documents for an Oct. 16 meeting of FDA’s Antimicrobial Drugs Advisory Committee to discuss IV cefiderocol from Shionogi & Co. Ltd. (Tokyo:4507) to treat...
BC Innovations | May 17, 2018
Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
BC Extra | Oct 11, 2017
Preclinical News

Researchers optimize gene editing for SCID

Researchers from Ospedale San Raffaele and elsewhere used zinc finger nuclease and CRISPR- Cas9 (CRISPR-associated protein 9)-based gene editing to correct hematopoietic stem/progenitor cells in animal models of SCID-X1, demonstrating improved gene editing protocols that...
BC Week In Review | Jul 11, 2016
Clinical News

Zalmoxis regulatory update

EMA’s CHMP recommended conditional approval of Zalmoxis from MolMed as an adjunctive treatment to aid immune reconstitution and reduce the risk of graft-versus-host disease (GvHD) in adults with high-risk hematological malignancies who are receiving a...
BC Extra | Jun 25, 2016
Company News

CHMP recommendations include Keytruda for NSCLC

EMA's CHMP recommended approval of PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) for non-small cell lung cancer, as well as asthma treatment Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and cell...
BC Innovations | Feb 4, 2016
Tools & Techniques

Calibrating CARs

Instead of focusing on how to turn chimeric antigen receptor (CAR) T cells off when things go wrong, a group at the California Institute for Biomedical Research (Calibr) has engineered a universal CAR T cell...
BC Innovations | Jul 23, 2015
Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
BC Week In Review | May 18, 2015
Company News

San Raffaele, MolMed deal

MolMed exercised an option to purchase a chimeric antigen receptor (CAR)- splice variant v6 of CD44 (CD44v6) from San Raffaele. MolMed said the compound has applications in hematological and solid tumors. The companies could not...
BC Week In Review | Apr 20, 2015
Financial News

MolMed completes rights offering

MolMed S.p.A. (Milan:MLM), Milan, Italy   Business: Cancer   Date completed: 2015-04-09   Type: Rights offering   Raised: EUR49.8 million ($52.6 million)   Shares: 187.3 million   Price: EUR0.27   Shares after offering: 421.5 million...
BC Week In Review | Oct 6, 2014
Financial News

MolMed completes private placement

MolMed S.p.A. (Milan:MLM), Milan, Italy   Business: Cancer   Date completed: 2014-09-26   Type: Private placement   Raised: EUR1.5 million ($1.9 million)   Shares: 3.1 million   Price: EUR0.49   Shares after offering: 234.1 million...
Items per page:
1 - 10 of 94